Long-Term Cost of the America's Healthy Future Act of 2009; As Passed by the Senate Finance Committee [PDF]
, 2009 Estimates the impact of the Senate Finance Committee's healthcare reform bill on health insurance coverage rates and net spending by federal, state, and local government with offsets; private employers; and families of various ages from 2010 through ...
John Sheils, Randy Haught
core
Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All
Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic +2 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Prescribing cascades occur when medication is prescribed to prevent/treat the adverse effects of another medication and may be intentional/unintentional. This study examines the prevalence of nine prescribing cascades (ThinkCascades) in The Irish Longitudinal StuDy on Ageing (TILDA).
Ann Sinéad Doherty +7 more
wiley +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Fuzzy multiattribute consumer choice among health insurance options
Technological and Economic Development of Economy, 2016 People buy insurance to protect themselves against possible financial loss in the future. Health insurance provides protection against the possibility of financial loss due to health care use.
Cengiz Kahraman +2 more
doaj +1 more source
The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs [PDF]
OBJECTIVE: To estimate the effect of differential cost sharing (DCS) schemes for non-steroidal anti-inflammatory drugs (NSAIDs) on drug subsidy program and beneficiary expenditures.
Adrian R. Levy +5 more
core
Realizing Health Reform's Potential: How the Affordable Care Act Will Strengthen Primary Care and Benefit Patients, Providers, and Payers [PDF]
, 2011 Examines issues in primary care and outlines the 2010 healthcare reform law's provisions to strengthen it, including temporary hikes in Medicare and Medicaid payments and support for innovations in care delivery and primary care workforce ...
Georgette Lawlor +3 more
core
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
The Value Driven Pharmacist: Basics of Access, Cost, and Quality 2nd Edition [PDF]
, 2020 https://digitalcommons.butler.edu/butlerbooks/1017/thumbnail ...
Devine, Trish +5 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer +4 more
wiley +1 more source